Exercise of options and PDMR dealing

MaxCyte, Inc.

06 November 2024

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Exercise of options and PDMR dealing

ROCKVILLE, MD, November 6, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 5 November 2024, as per a filing lodged with the U.S. Securities and Exchange Commission, Stanley Erck, a Non-Executive Director of the Company, exercised options over 47,689 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 47,689 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by Stanley Erck at a price range between $3.610 and $3.755 per Common Stock ("Sale"). The sold shares represent approximately 8.04% of Stanley Erck's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, Stanley Erck holds 247,751 shares of Common Stock representing 0.2% of the issued stock capital of the Company. Following the Exercise, Stanley Erck holds a further 276,501 options over Common Stock and 21,367 restricted stock units.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Stanley Erck on 12 March 2024 relating solely to the sale of shares acquired from exercise of options that expire on 11 November 2024.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA 

[phone]

[e-mail]

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden         

[phone]

UK IR Adviser

ICR Healthcare

Mary-Jane Elliott

Chris Welsh    

[phone]

[e-mail]

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stanley Erck
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
	Identification code	US57777K1060
b)	Nature of the transaction	Exercise of Options over common stock
c)	Price(s) and volume(s)
			Exercise Price(s)	Volume(s)
			$0.040	47,689
d)	Aggregated information
	- Aggregated volume	47,689
	- Price	$0.040
e)	Date of the transaction	1 November 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq
1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stanley Erck
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
	Identification code	US57777K1060
b)	Nature of the transaction	Sale of common stock
c)	Price(s) and volume(s)
			Exercise Price(s)	Volume(s)
			$3.6100	100
			$3.6400	100
			$3.6450	200
			$3.6500	1500
			$3.6550	1370
			$3.6600	500
			$3.6650	290
			$3.6700	774
			$3.6750	780
			$3.6800	550
			$3.6850	1150
			$3.6900	650
			$3.6950	3312
			$3.7000	5910
			$3.7050	1626
			$3.7100	888
			$3.7150	1375
			$3.7200	5460
			$3.7250	330
			$3.7300	4667
			$3.7350	675
			$3.7400	6010
			$3.7450	795
			$3.7500	7297
			$3.7550	1380
d)	Aggregated information
	- Aggregated volume	47,689
	- Price	$3.7157
e)	Date of the transaction	1 November 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

 

END